The PBAC has recommended two adalimumab biosimilars for PBS listing. The two listings — for Amgevita (Amgen Australia) and…
Read more
No need to beef up PPI warnings Warnings of cardiovascular risk from use of proton pump inhibitors do not need to be beefed…
Read more
Pharmacists are set to be given the power to substitute a biologic drug for a biosimilar just two months after the…
Read more
Opposition and crossbench senators passed the government’s PBS reform package yesterday despite serious misgivings about…
Read more
Debate is flaring up over whether pharmacists should be able to switch patients to biosimilar medicines. As part of its PBS…
Read more